Heavy Metals Testing by ICP-MS

Heavy metals testing by inductively coupled plasma mass spectrometry, commonly abbreviated ICP-MS, determines which elemental impurities are present in a sample and at what concentration. Where chromatographic purity testing quantifies organic compounds relative to one another, ICP-MS addresses an entirely separate question: the inorganic elemental composition of the material. The technique is capable of detecting most elements in the periodic table at concentrations in the parts-per-billion to parts-per-trillion range, which makes it the preferred method for pharmaceutical elemental impurity work under both ICH Q3D and the United States Pharmacopoeial general chapters USP <232> and <233>.

How ICP-MS works

The measurement begins with sample preparation. Pharmaceutical and peptide samples are solid or semi-solid materials that must be converted to a clear aqueous solution before introduction into the instrument. This is typically accomplished by acid digestion, most commonly using concentrated nitric acid in a closed-vessel microwave digestion system. The high pressure and temperature inside the sealed vessel drives complete decomposition of the organic matrix, leaving elemental constituents dissolved in dilute acid. The process is destructive. Once digested, the original sample cannot be recovered.

The resulting solution is then introduced into the instrument by a peristaltic pump. A nebuliser converts the liquid into a fine aerosol, and a spray chamber removes the largest droplets so that only the finest particles reach the plasma. The plasma itself is an extremely hot ionised argon gas, sustained at temperatures between roughly 6,000 and 10,000 Kelvin by a radiofrequency coil. At those temperatures, the aerosol droplets are successively desolvated, vaporised, atomised and finally ionised. Nearly every element in the periodic table loses at least one electron under these conditions, forming positively charged ions.

These ions are extracted from the plasma through a pair of metal cones, called the sampler and skimmer cones, into a high-vacuum region where the mass spectrometer operates. Inside the mass analyser, most commonly a quadrupole, ions are separated according to their mass-to-charge ratio. Only ions of a specific ratio pass through to the detector at any given moment, and the instrument cycles rapidly through all masses of interest. The detector counts arriving ions and the count rate at each mass is proportional to the concentration of that element in the original sample. Calibration against solutions of known concentration converts count rates into quantitative results, typically expressed in micrograms per gram, micrograms per litre, parts per million or parts per billion depending on the context and the regulatory framework being applied.

Where trace metals enter during synthesis

Understanding where elemental impurities originate is relevant to interpreting a result. In solid-phase peptide synthesis, the most common route to the final peptide, potential sources include the following.

• Raw materials and reagents. Amino acid building blocks, coupling reagents, solvents and resins are synthesised from chemical feedstocks that may carry trace metal impurities. Reagent-grade materials carry lower impurity burdens than technical-grade equivalents, but the relevant question is always the actual measured concentration, not the nominal grade.
• Metal catalysts. Some synthetic steps, particularly in the preparation of non-standard amino acid building blocks or small-molecule active pharmaceutical ingredients, use palladium, nickel or other transition metal catalysts. Residual catalyst in the final product is a well-recognised concern and a specific focus of the ICH Q3D framework.
• Water and solvents. Water used in reconstitution, washing and final preparation can carry trace metals if not properly purified. Highly purified water, such as water for injection quality, substantially reduces this contribution, but it does not eliminate it.
• Equipment and hardware. Stainless steel reactors, piping, chromatography column hardware and other process-contact surfaces contain iron, nickel, chromium and manganese. Under certain conditions, particularly with acidic process streams, these surfaces leach trace quantities of their constituent metals into the product.
• The manufacturing environment. Airborne particulates containing lead, cadmium and other environmental metals can contaminate open process streams or inadequately protected intermediate materials.
• Packaging and containers. Glass and polymer packaging can contribute trace metals, particularly if the material has not been validated for compatibility with the product.

No single source dominates in all cases. The risk assessment framework in ICH Q3D is designed to guide manufacturers through a systematic evaluation of each potential source specific to their process, rather than assuming a generic contamination profile.

The regulatory framework: ICH Q3D and USP 232/233

The primary international framework for elemental impurities in pharmaceuticals is ICH Q3D, a harmonised guideline developed through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. USP general chapters <232> (Elemental Impurities, Limits) and <233> (Elemental Impurities, Procedures) implement compatible requirements within the United States pharmacopoeial system. Both align on the same classification structure and Permitted Daily Exposure concept.

ICH Q3D classifies 24 elements of concern into four groups. Class 1 comprises arsenic, cadmium, mercury and lead. These elements have established human toxicity and have little or no legitimate role in pharmaceutical manufacturing. They attract the most stringent limits. Class 2A comprises cobalt, nickel and vanadium, elements with higher probability of occurrence in drug products and route-dependent toxicity profiles. Class 2B includes elements that are also route-dependent toxicants but less likely to be encountered in practice. Class 3 covers elements with lower toxicity concern at the concentrations typically found in pharmaceuticals.

The framework expresses limits through the concept of the Permitted Daily Exposure, or PDE. A PDE is the maximum acceptable daily intake of an element via a given route, expressed in micrograms per day. ICH Q3D specifies separate PDE values for oral, parenteral and inhalation administration for each of the 24 listed elements. Because the same element can have very different bioavailability and systemic effects depending on whether it passes through the gastrointestinal tract or is injected directly, the limits for parenteral products are generally lower than for oral products. A laboratory result expressed as a concentration in micrograms per gram cannot be interpreted as compliant or non-compliant without knowing the dosage form, the dose per administration and the route.

Concentration limits reported in parts per million or parts per billion are derived from PDEs by dividing the PDE by the maximum daily dose of the product. This means the same concentration of an element may be acceptable in a low-dose product and unacceptable in a high-dose product. Reporting the raw concentration alongside the PDE calculation, or alongside the method detection limit if the element was not detected, gives a result that can actually be applied to a regulatory assessment.

Interferences and how they are managed

ICP-MS is sensitive to a class of measurement artefact called polyatomic or isobaric interferences. These arise when atoms present in the plasma or the sample matrix combine to form molecular ions with the same mass-to-charge ratio as the target analyte, causing the instrument to over-report that element's concentration. The plasma itself is a source of interfering species because argon is ubiquitous and forms clusters with oxygen, nitrogen, carbon and other elements present in the sample.

Two of the most practically significant interferences involve elements covered by Class 1 of ICH Q3D. Arsenic has only one naturally occurring stable isotope at mass 75. In samples containing chloride, argon from the plasma combines with chlorine to produce the ion at mass 75, sitting directly on top of the arsenic signal. Similarly, several selenium isotopes are affected by argon-oxygen cluster ions. Uncorrected, these interferences cause apparent elevations in measured concentrations that are artefactual, not real.

Modern instruments address this with a collision or reaction cell inserted between the ion optics and the mass analyser. When operated in collision mode, a gas such as helium is introduced into the cell. Polyatomic ions, which are larger than monatomic analyte ions, lose more energy through collisions with the gas and are discriminated against by an energy barrier downstream. When operated in reaction mode, a reactive gas such as hydrogen is used. The reactive gas converts the interfering species to a harmless product at a different mass, while the analyte ion passes through with reduced interference. Method validation for ICP-MS applied to pharmaceutical elemental impurity work requires demonstration that interferences for the relevant elements have been adequately characterised and controlled.

What a result describes, and what it does not

An ICP-MS result describes the elemental composition of the digested solution prepared from the sample submitted for testing. It does not describe any other batch, any other lot, or any other container of material bearing the same label. As with any analytical certificate, the result is specific to the sample received.

Several aspects of result interpretation deserve attention.

• Sample preparation matters. Incomplete digestion leaves a portion of the sample undigested, which means some metal content remains unextracted and will not be measured. Results from an incompletely digested sample understate the true concentration. Complete digestion is a prerequisite for a valid result, and method validation should demonstrate recovery for each analyte in the matrix type being tested.
• "Not detected" has a defined meaning. When a result is reported as not detected, it means the signal at that mass did not exceed the method's limit of detection for that element under those conditions. The limit of detection depends on the instrument, the specific element and the sample matrix. A responsible report states what that limit was, so the reader can assess whether the sensitivity was adequate for the intended application.
• Concentration is not the same as compliance. A reported concentration in micrograms per gram tells you how much of an element was present in the sample. Whether that concentration represents a compliant result under ICH Q3D requires additional information: the route of administration, the daily dose and the specific PDE for that element by that route. These inputs are the responsibility of the person commissioning the test and applying the result to a product, not the laboratory conducting the measurement.
• Heavy metals testing does not substitute for chromatographic purity testing. A sample that passes elemental impurity limits may still contain organic impurities, synthesis by-products or incorrect sequence peptides. The two test categories address different dimensions of product quality and are complementary, not interchangeable.

Relationship to other safety-relevant tests

Elemental impurity testing sits alongside other safety-relevant analytical tests that address distinct contamination types. Endotoxin testing measures bacterial lipopolysaccharides, a biological contaminant that ICP-MS cannot detect. Sterility testing addresses microbial viability. Residual solvent analysis by gas chromatography covers organic solvents not visible to ICP-MS. Each test type answers a specific question about a specific class of potential contaminant. A comprehensive quality picture requires an understanding of which tests are necessary for a given product and route, not the assumption that any one test is sufficient.

Reference standards play a role in elemental analysis as well. Certified reference solutions of known elemental concentration are used to calibrate the instrument and to verify that the method is performing as expected on the day of analysis. Without calibration traceability to certified reference materials, concentration figures carry undefined uncertainty. This is discussed further in the context of reference standards in peptide testing.

Commissioning a heavy metals test

Submitting a sample for ICP-MS elemental impurity testing requires a modest amount of planning. The laboratory needs to know the intended route of administration and the anticipated maximum daily dose so that the result can be contextualised against the appropriate PDE values. It also needs adequate sample quantity, because acid digestion is destructive and the instrument requires sufficient material to prepare a solution of appropriate concentration. The minimum sample requirement will vary between laboratories and between product types.

The result will be delivered as a certificate listing each element analysed, the measured concentration or a not-detected finding with the associated detection limit, and typically the applicable PDE or concentration limit derived from PDE for the stated route and dose. A certificate that reports only a raw concentration without the detection limit for not-detected results, or without reference to the applicable limit, provides incomplete information for regulatory or quality decision-making.

Certificates issued by Novagen carry a unique verification key that can be checked against the public register at novagenlaboratories.com/verify. The register records the result as it was issued and cannot be altered retrospectively. Current turnaround is 21 days from receipt of samples. Enquiries can be directed to admin@novagenlaboratories.com.

Summary

ICP-MS detects and quantifies elemental impurities at concentrations a conventional analytical balance or chromatographic system cannot approach. It is the technique referenced by ICH Q3D and USP <232>/<233> for precisely this reason. The measurement depends on complete sample digestion, careful interference management and calibration traceable to certified reference materials. A result describes what was measured in the submitted sample, expressed as a concentration. Converting that concentration to a regulatory determination requires knowing the dosage form, the route of administration and the daily dose, and applying the Permitted Daily Exposure values specified for each element and route in the relevant pharmacopoeial framework. Heavy metals testing addresses one axis of product quality. Chromatographic purity, identity confirmation, endotoxin and residual solvents address others. No single test is comprehensive.